Neurocrine Biosciences (NBIX) Profit After Tax (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Profit After Tax for 17 consecutive years, with $149.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax rose 34.32% year-over-year to $149.1 million; the trailing twelve-month figure through Jun 2026 stood at $710.8 million (up 97.72% YoY), and the FY2025 full-year result was $485.9 million, up 42.37% from the prior year.
• Profit After Tax slipped to $149.1 million in Q2 2026 per NBIX's latest filing, from $197.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at $210.2 million in Q3 2025 and bottomed at -$76.6 million in Q1 2023.
• Historically, Profit After Tax has averaged $88.4 million across 5 years, with a median of $92.3 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Profit After Tax plunged 651.08% in 2023, then jumped 1682.88% in 2026.
• Over 5 years, Profit After Tax stood at $89.0 million in 2022, then jumped by 75.73% to $156.4 million in 2023, then plunged by 38.87% to $95.6 million in 2024, then soared by 60.67% to $153.6 million in 2025, then retreated by 2.93% to $149.1 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $149.1 million, $197.9 million, and $153.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.